The UAB and Pharmacelera sign an agreement to research into new drugs for Parkinson's disease
Researchers from the IBB-UAB will develop a research project with the company Pharmacelera to find new molecules capable of blocking the alpha-synucleic protein, the accumulation of which is the main factor causing Parkinson's disease.
![SynuClean-D](/Imatge/763/22/Imatge_2,248.jpg)
Now thanks to the agreement signed with Pharmacelera the group will develop an in silico clinical trial (computer simulation) of molecules derived from SynuClean-D with the aim of obtaining more suitable candidates to be used to treat Parkinson's disease. The group will use the company's emblematic software PharmScreen® in order to conduct selection campaigns in large virtual libraries and find these new candidate molecules.
"The in silico selection technologies will be a key complement to our experimental approach", Salvador Ventura points out. "Pharmacelera has the technology needed to discover drugs which will help guide our next steps in improving the quality of new candidates, given that it will make its identification more efficient and save us time and efforts", he adds.
"Pharmacelera, as a specialist in drug design software, has broad experience in similar drug discovery projects, and we are sure that PharmScreen® will play a key role in proposing new candidates for the treatment of Parkinson's disease”, states Pharmacelera's CEO Enric Gibert.